-
March 03, 2011
Salix has taken another blow from the FDA, but seems too cheap given its prospects.
-
March 01, 2011
Novavax gets a sizable contract from the government that will largely fund its remaining clinical trials for flu ...
-
February 03, 2011
The market is praising Pfizer's decision to cut back on R&D and focus funds on repurchasing its attractively-priced ...
-
January 27, 2011
Looking across the pond at the UK, one can't help but be attracted to some of the opportunities.
-
January 26, 2011
Hi-Tech Pharmacal is a micro-cap generic drug manufacturer that has had very solid profits in recent months.
-
January 20, 2011
The ongoing financial crisis in the European Union has made the United Kingdom a promising prospect for value ...
-
January 19, 2011
Will Forest be able to plug a gaping hole in its future revenue?
-
December 21, 2010
Possible European approval could save the day for this risky biotech.
-
December 08, 2010
Will another new drug company CEO make a difference in a stagnating industry?
-
November 17, 2010
HGSI's prospects get a big boost from a panel approval.
-
November 08, 2010
Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact ...
-
July 28, 2010
This drug distribution company is reaping the benefits of drug patent expiration and the government's new focus on ...
-
July 28, 2010
The Sanofi/Genzyme combination isn't the only biotech M&A activity on the radar.
-
July 23, 2010
There's more to the story than one lousy quarter for PetMed Express and Gilead.
-
July 07, 2010
Dendreon has put cancer vaccines back in the spotlight, but can they live up to their hype?
-
June 30, 2010
Amgen is being treated like just another Big Pharma laggard, but analysis suggests there is more growth potential here.
-
June 22, 2010
Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions?
-
June 15, 2010
Stem cells get a lot of attention, but maybe not in the one area where they could prove most effective.
-
June 08, 2010
Amgen hopes for a boost in revenue from their just-approved multi-purpose drug, Prolia.
-
June 04, 2010
Stocks of some of the large pharmaceutical companies are now available at attractive prices.
